JBS Science
Private Company
Funding information not available
Overview
JBS Science is a privately-held diagnostics company founded in 2008 and incorporated in 2011, headquartered in San Diego, CA. It has developed proprietary technologies for cfDNA isolation and sensitive qPCR assays, aiming to detect primary and recurrent cancers via a simple urine test. The company has been primarily funded through multiple NIH SBIR grants, including a significant $3 million Bridge Award from the NCI, and has established key collaborations and a licensing agreement for its isolation kits. Its current focus appears to be on liver cancer (HCC) screening, with data presented at major hepatology and oncology conferences.
Technology Platform
Proprietary methods for isolating cell-free DNA (cfDNA) from urine and blood, coupled with sensitive qPCR assays for detecting tumor DNA markers. Also commercializes the semi-automated JPurX system for nucleic acid isolation.
Opportunities
Risk Factors
Competitive Landscape
JBS Science competes in the liquid biopsy diagnostics market against major players like Guardant Health and Exact Sciences, which focus on blood-based tests. Its primary differentiation is the use of urine as a sample source. It also competes with other companies developing urine-based cancer biomarkers, though its specific cfDNA technology and focus on HCC may provide niche advantages.